What is Kymera Therapeutics, Inc.'s Shariah compliance score?

Kymera Therapeutics, Inc.'s (KYMR) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Kymera Therapeutics, Inc. pass AAOIFI screening?

Kymera Therapeutics, Inc. (KYMR) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (KYMR: 1.2%), (3) interest-bearing deposits below 30% (KYMR: 8.5%), and (4) prohibited income below 5% (KYMR: 40.3%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Kymera Therapeutics, Inc. stock?

Kymera Therapeutics, Inc. (KYMR) has a non-permissible income ratio of 40.35%. Muslim investors should purify this percentage of any dividends received and capital gains realized from KYMR shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Kymera Therapeutics, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Kymera Therapeutics, Inc. (KYMR) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about KYMR's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Kymera Therapeutics, Inc. (KYMR) halal? Not Halal. Based on AAOIFI screening, Kymera Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

KYMR: Is Kymera Therapeutics, Inc. Halal?

Not Halal

Kymera Therapeutics, Inc.

NASDAQHealthcareUS

$82.96

+6.05%

AvoidBorderlineClean

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 12, 2026

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap1.2% / 30.0%

Compliance History

Not Halalnow
since Jun 2026
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 12, 2026Fiscal: Q1 2026Source: FMP

Financial Overview

Market Cap

6.8B

Price

$82.96

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track KYMR and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Kymera Therapeutics, Inc. (KYMR) halal to invest in?

Kymera Therapeutics, Inc. (KYMR) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Kymera Therapeutics, Inc. get a F compliance rating?

Kymera Therapeutics, Inc. (KYMR) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.2% (limit 30%); interest-bearing deposits of 8.5% (limit 30%); prohibited income of 40.35% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Kymera Therapeutics, Inc.'s Shariah verdict?

Kymera Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Kymera Therapeutics, Inc. re-screened for Shariah compliance?

Kymera Therapeutics, Inc. (KYMR) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 12, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.